
    
      To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and
      radiofrequency ablation.

      The 23 patients were enrolled in a 3-week regimen with 200mg Camrelizumab given intravenously
      every 3weeks and 250mg apatinib mesylate qd ï¼Œand 850mg/m2 capecitabine d1-14 and 130mg/m2
      oxaliplatin given intravenously d1.
    
  